ClinicalTrials.gg
TerminatedNCT03997474Updated Mar 7, 2025Results posted

ATL001 in Patients With Metastatic or Recurrent Melanoma

A Phase 1/2 interventional study of ATL001 and Checkpoint Inhibitor in Melanoma, sponsored by Achilles Therapeutics UK Limited. Terminated at 10 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-07.

Sponsored by Achilles Therapeutics UK Limited · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 269 studies in Melanoma with a site in United Kingdom — 31 open to participants now, 73 under way, 24 of them phase 3. Melanoma · United Kingdom.

Enrollment
208th of 226
13 · median 183
Started
2019
with 14 others
Phase 1/2
35 of 269
5 open now
Registered
165th of 269
by date

Among the 269 studies in Melanoma with a site in United Kingdom, this one is the 208th largest by enrollment of the 226 interventional ones that give a count, is one of 15 that started in 2019, is one of 35 in phase 1/2, and was the 165th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

31 of the 269 studies in Melanoma with a site in United Kingdom are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 269 studies in Melanoma with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterize the safety and clinical activity of ATL001, autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with metastatic or recurrent melanoma.

Read the detailed description

This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterize the safety and clinical activity autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with metastatic or recurrent melanoma.

Patients will initially enter the study for procurement of tumour materials required to manufacture ATL001.Following manufacture of ATL001, the product will be given back to eligible patients following lymphodepletion.

Patients will be followed up for a period of 24 months post ATL001 infusion in the study.

Patients will continue to be followed up for a minimum of 5 years, as part of a separate Long Term Follow Up Protocol, or, if the separate protocol is not available at the study site, within this protocol.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must be at least 18 years old.
  2. Patient must have given written .
  3. Patients must have confirmed diagnosis of melanoma.
  4. Patient is considered medically fit to undergo procurement of starting material and ATL001 administration procedures.
  5. Performance Status 0-1.
  6. Adequate organ function per the laboratory parameters defined in the protocol.
  7. Female patients who are of must agree to use a highly effective method of during the study for at least 12 months after the ATL001 infusion. Non-sterilised male participants who intend to be sexually active with a female partner of childbearing potential must use an acceptable method of contraception from the time of screening, throughout the duration of the study and for at least 6 months after the ATL001 infusion.
  8. Anticipated ≥ 6 months at the time of tissue procurement.
  9. according to v1.1 criteria. Additional inclusion criteria will apply as per the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Patients with known or untreated, symptomatic or progressing central nervous system (CNS) . Lesions should be clinically and radiologically stable for 2 months after treatment and should not require .
  2. Patients with ocular, acral or mucosal melanoma.
  3. Patients with or C, infection (HIV 1/2), syphilis or HTLV I/II infection.
  4. Patients requiring treatments.
  5. Patients requiring regular steroids at a dose higher than prednisolone 10mg/day (or equivalent).
  6. Patients with , progressive, and/or uncontrolled renal, hepatic, haematological, endocrine, pulmonary, cardiac, gastroenterological, or neurological disease.
  7. Patients with a history of immune mediated (CNS) toxicity or ≥ Grade 2 diarrhoea/colitis caused by, , previous immunotherapy within the past 6 months.
  8. Patients who are pregnant or breastfeeding.
  9. Patients who have undergone major surgery in the previous 3 weeks.
  10. Patients with an active concurrent cancer or a history of cancer within the past 3 years (except for in situ carcinomas, early prostate cancer with normal Prostate-Specific Antigen (PSA) or non-melanomatous skin cancers).
  11. Patients with a history of organ transplantation.
  12. Patients who have previously received any cell or gene therapies.
  13. Patients with for protocol specified agents.

Additional Exclusion criteria will apply as per the study protocol.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Cohort A

    Following lymphodepletion, infusion of cell therapy product ATL001, followed by a low dose regimen of IL- 2.

    Biological: ATL001

  • Experimental
    Cohort B

    Following lymphodepletion, infusion of cell therapy product ATL001 in combination with a checkpoint inhibitor, followed by a low dose regimen of IL-2.

    Biological: ATL001 · Drug: Checkpoint Inhibitor

  • Experimental
    Cohort C

    Following lymphodepletion, infusion of cell therapy product ATL001, followed by a higher dose regimen of IL-2.

    Biological: ATL001

Interventions

  • BiologicalATL001

    ATL001 infusion

  • DrugCheckpoint Inhibitor

    Nivolumab

This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Assessment of Treatment Emergent Adverse Events to Evaluate Safety and Tolerability: CTCAE

    Evaluate treatment-emergent adverse events (TEAEs) and serious AEs, per CTCAE, by incidence, severity and relationship to ATL001

    Time frame: 60 months due to early termination

Secondary outcomes

  1. Disease Assessment for Change From Baseline in Tumour Size

    Evaluate the clinical activity of ATL001 in patients with recurrent or metastatic melanoma using change from baseline in tumour size at week 6, week 12 and best overall change from baseline, as assessed by investigator and independent central review (ICR).

    Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

  2. Disease Assessment for Overall Response Rate

    Evaluate the endpoint of overall response rate (ORR), as assessed by investigator and ICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and immune modified RECIST( im-RECIST). RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) is a standardized system for measuring tumor response to treatment in clinical trials. Tumors are assessed by imaging (e.g., CT or MRI) based on changes in size. Responses are categorized as: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): ≥30% reduction in the sum of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD). Progressive Disease (PD): ≥20% increase in the sum of target lesions, or appearance of new lesions. These criteria help assess the efficacy of treatments in solid tumors supported by im-RECIST in immunotherapy.

    Time frame: Every 6 weeks for 6 months, then every 3 months (up to 60 months due to early study termination)

  3. Disease Assessment for Time to Response and Duration of Response

    Evaluate the endpoints of time to response and duration of response (DOR) by the investigator and ICR, per RECIST v1.1 and im-RECIST.

    Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

  4. Disease Assessment for Disease Control Rate

    Evaluate the endpoints of disease control rate (DCR) as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST.

    Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

  5. Disease Assessment for Progression-Free Survival

    Evaluate the efficacy endpoints of progression-free survival (PFS) as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST.

    Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

  6. Overall Survival

    Evaluate overall survival (OS) by investigator

    Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

07

Results

Posted Mar 7, 2025

Participant flow

Participant flow — Overall Study
MilestoneCohort ACohort BCohort C
Started922
Completed000
Not completed922
Withdrew: Death621
Withdrew: Physician decision200
Withdrew: Study terminated by sponsor101

Outcome measures

PrimaryAssessment of Treatment Emergent Adverse Events to Evaluate Safety and Tolerability: CTCAE

Evaluate treatment-emergent adverse events (TEAEs) and serious AEs, per CTCAE, by incidence, severity and relationship to ATL001

Time frame:
60 months due to early termination
Reported as:
Count of participants · Participants
Assessment of Treatment Emergent Adverse Events to Evaluate Safety and Tolerability: CTCAE
ParticipantsCohort ACohort BCohort C
TEAEs922
TEAEs related to any component of study treatment822
Lymphodepletion related TEAEs812
ATL001 related TEAEs IL-2 related TEAEs Serious TEAEs522
IL-2 related TEAEs722
Nivolumab related TEAEs000
Serious TEAEs310
Serious TEAEs related to any component of study treatment110
Serious Lymphodepletion related TEAEs000
Serious ATL001 related TEAEs110
Serious IL-2 related TEAEs110
Serious Nivolumab related TEAEs000
TEAEs with CTCAE grade >= 3621
TEAEs with CTCAE grade >= 3 related to any component of study treatment521
Lymphodepletion related TEAEs with CTCAE grade >= 3411
ATL001 related TEAEs with CTCAE grade >= 3210
IL-2 related TEAEs with CTCAE grade >= 3220
Nivolumab related TEAEs with CTCAE grade >= 3010
TEAEs leading to death010
TEAEs leading to death related to any component of study treatment000
SAEs321
SecondaryDisease Assessment for Change From Baseline in Tumour Size

Evaluate the clinical activity of ATL001 in patients with recurrent or metastatic melanoma using change from baseline in tumour size at week 6, week 12 and best overall change from baseline, as assessed by investigator and independent central review (ICR).

Time frame:
Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

Results for this outcome have not been posted.

SecondaryDisease Assessment for Overall Response Rate

Evaluate the endpoint of overall response rate (ORR), as assessed by investigator and ICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and immune modified RECIST( im-RECIST). RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) is a standardized system for measuring tumor response to treatment in clinical trials. Tumors are assessed by imaging (e.g., CT or MRI) based on changes in size. Responses are categorized as: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): ≥30% reduction in the sum of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD). Progressive Disease (PD): ≥20% increase in the sum of target lesions, or appearance of new lesions. These criteria help assess the efficacy of treatments in solid tumors supported by im-RECIST in immunotherapy.

Time frame:
Every 6 weeks for 6 months, then every 3 months (up to 60 months due to early study termination)
Reported as:
Count of participants · Participants
Disease Assessment for Overall Response Rate
ParticipantsCohort ACohort BCohort C
Responders000
Non-Responders922
SecondaryDisease Assessment for Time to Response and Duration of Response

Evaluate the endpoints of time to response and duration of response (DOR) by the investigator and ICR, per RECIST v1.1 and im-RECIST.

Time frame:
Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

Results for this outcome have not been posted.

SecondaryDisease Assessment for Disease Control Rate

Evaluate the endpoints of disease control rate (DCR) as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST.

Time frame:
Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

Results for this outcome have not been posted.

SecondaryDisease Assessment for Progression-Free Survival

Evaluate the efficacy endpoints of progression-free survival (PFS) as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST.

Time frame:
Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

Results for this outcome have not been posted.

SecondaryOverall Survival

Evaluate overall survival (OS) by investigator

Time frame:
Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months

Results for this outcome have not been posted.

Adverse events

Collected over Each patient that received ATL001 would have been followed up for 24 months, to withdrawal of consent or death. Patients would then continue to be followed up for a minimum of 5 years as part of long term follow up. The study was terminated early due to sponsor decision. The Median follow-up period was 12 weeks (range: 3 - 48 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A8/9 (88.9%)3/9 (33.3%)9/9 (100%)
Cohort B2/2 (100%)2/2 (100%)2/2 (100%)
Cohort C1/2 (50%)1/2 (50%)2/2 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventCohort ACohort BCohort C
Procedural painInjury, poisoning and procedural complications0/90/21/2
Immune effector cell-associated neurotoxicity syndromeNervous system disorders1/91/20/2
Adrenal insufficiencyEndocrine disorders0/91/20/2
Pneumonia aspirationInfections and infestations0/91/20/2
SepsisInfections and infestations2/90/20/2
Abdominal wall infectionInfections and infestations1/90/20/2
Klebsiella sepsisInfections and infestations1/90/20/2
ConstipationGastrointestinal disorders1/90/20/2
Drain site complicationInjury, poisoning and procedural complications1/90/20/2
HaematuriaRenal and urinary disorders1/90/20/2
Most frequent other events
Showing 10 of 123
Most frequent other events
EventCohort ACohort BCohort C
FatigueGeneral disorders3/91/22/2
AnaemiaBlood and lymphatic system disorders4/92/22/2
ConstipationGastrointestinal disorders3/92/21/2
NauseaGastrointestinal disorders6/92/21/2
Lymphocyte count decreasedInvestigations3/92/20/2
FallInjury, poisoning and procedural complications0/92/20/2
DyspnoeaRespiratory, thoracic and mediastinal disorders1/92/20/2
NeutropeniaBlood and lymphatic system disorders7/90/21/2
PyrexiaGeneral disorders6/91/21/2
DiarrhoeaGastrointestinal disorders5/91/20/2

Baseline characteristics

No differences.

Age, Categorical
Age, Categorical(Participants)Cohort ACohort BCohort CTotal
<=18 years0000
Between 18 and 65 years82212
>=65 years1001
Age, Continuous
Age, Continuous(years)Cohort ACohort BCohort CTotal
Mean50.4 ± 10.4959.5 ± 4.9536.5 ± 4.9549.7 ± 11.09
Sex: Female, Male
Sex: Female, Male(Participants)Cohort ACohort BCohort CTotal
Female2024
Male7209
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort ACohort BCohort CTotal
Hispanic or Latino0000
Not Hispanic or Latino92213
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort ACohort BCohort CTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White92213
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Cohort ACohort BCohort CTotal
United Kingdom92112
Spain0011
Body mass index (kg/m^2)
Body mass index (kg/m^2)(kg/m^2)Cohort ACohort BCohort CTotal
Mean28.52 ± 4.92225.55 ± 2.05222.90 ± 1.83827.2 ± 4.651
Baseline ECOG performance status
Baseline ECOG performance status(Participants)Cohort ACohort BCohort CTotal
Grade 02114
Grade 17119
08

Study locations

10 sites
  • Instituto de Investigación Sanitaria Fundación Jimenez Díaz
    Madrid, 28040, Spain
  • Centro Integral Oncologico Clara Campal (CIOCC) Hospital Universitario HM Sanchinarro
    Madrid, 28050, Spain
  • Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital
    Cambridge, CB2 0QQ, United Kingdom
  • University College London Hospitals (UCLH) NHS Foundation Trust, University College Hospital
    London, NW12PG, United Kingdom
  • Royal Free London NHS Foundation Trust, Royal Free Hospital
    London, NW3 2QG, United Kingdom
  • Guys and St Thomas' NHS Foundation Trust, Guy's Hospital
    London, SE19RT, United Kingdom
  • The Royal Marsden NHS Foundation Trust, The Royal Marsden Hospital
    London, SW3 6JJ, United Kingdom
  • The Christie NHS Foundation Trust, Christie Hospital
    Manchester, M20 4BX, United Kingdom
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital
    Newcastle Upon Tyne, NE7 7DN, United Kingdom
  • University Hospital Southampton NHS Foundation Trust, Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Sep 2024, 60 months.

Results were first posted in Mar 2025, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2019
First posted
Jun 25, 2019
StartActual
Aug 15, 2019
Primary completionActual
Sep 3, 2024
CompletionActual
Sep 3, 2024
Results first posted
Mar 7, 2025
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03997474
Lead sponsor
Achilles Therapeutics UK Limited
Responsible party
Sponsor
First posted
Jun 25, 2019
Start date
Aug 15, 2019
Primary completion
Sep 3, 2024
Completion
Sep 3, 2024
Results posted
Mar 7, 2025
Last update
Mar 7, 2025

Study contacts

Medical Monitor, MD
study director · Achilles Therapeutics UK Limited

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Clonal Neoantigen T Cells ATL001

Start the discussion